Fosamax (Alendronate) in Your 60s and Beyond: What Every Woman Should Know

Why Your 60s Is a Defining Decade for Bone Health

Your 60s are not just the start of something new. They are the decade when the accelerated bone loss triggered by menopause transitions into a slower but relentless background rate of about 1% per year, and when your lifetime fracture risk becomes concrete and calculable. By age 65, approximately 1 in 4 women has osteoporosis at the hip or lumbar spine, and that proportion climbs steadily through the 70s and 80s.

The mechanism is straightforward. Estrogen normally restrains osteoclast activity, the cells that break down bone. After menopause, that brake lifts. Alendronate works by binding tightly to hydroxyapatite on bone surfaces and poisoning osteoclasts from the inside, slowing resorption without directly stimulating new bone formation. The net effect is a gradual increase in bone mineral density (BMD) and, more importantly, a measurable drop in fracture rates.

What Happens to Bone in the Post-60 Body

After the first five years post-menopause, the rapid phase of bone loss (averaging 2-3% per year at the lumbar spine) slows. But in your 60s you are also accumulating microarchitectural deterioration, thinner trabeculae, and reduced bone quality that BMD alone does not fully capture. The FRAX tool integrates age, BMD, and clinical risk factors to produce a 10-year fracture probability. Current National Osteoporosis Foundation guidelines, endorsed by ACOG, recommend treatment when your 10-year probability of major osteoporotic fracture reaches 20% or hip fracture reaches 3%, even if your T-score has not yet crossed the -2.5 threshold.

Hormonal Status and Drug Effectiveness

Alendronate does not depend on your estrogen level to work. Its antiresorptive effect is independent of hormonal milieu, which is why it performs consistently across early postmenopause, late postmenopause, and in women who have undergone surgical menopause. A pooled analysis published in the Journal of Bone and Mineral Research confirmed that alendronate's fracture reduction was consistent regardless of baseline estradiol levels, a meaningful distinction from hormone therapy (HT), whose skeletal benefits fade within a few years of stopping.

If you are using concurrent menopausal hormone therapy, the combination produces additive BMD gains compared with either agent alone, though no randomized trial has yet shown that the combination reduces fracture rates beyond what each agent achieves separately. Most clinicians reserve combination use for women with severe bone loss who are also managing significant vasomotor symptoms.

The Evidence: What Alendronate Actually Does to Fracture Risk

The Fracture Intervention Trial (FIT) remains the cornerstone evidence base. In FIT, alendronate reduced clinical vertebral fracture risk by 55% and hip fracture risk by 51% in postmenopausal women with a femoral neck T-score of -2.5 or lower and at least one existing vertebral fracture. These women were largely in their 60s and 70s, making the data directly applicable to you.

FIT-1 vs FIT-2: Which Women Benefit Most?

The FIT trial had two arms. FIT-1 enrolled women with prevalent vertebral fractures; FIT-2 enrolled women with low BMD but no prevalent fracture. In FIT-1, fracture benefits were clear and statistically strong. In FIT-2, the hip fracture reduction reached significance only in the subgroup with T-scores at or below -2.5. This distinction matters clinically: if your T-score is in the osteopenia range (-1.0 to -2.49) and you have no prior fractures, alendronate's fracture benefit is less certain and the decision should factor in your FRAX score, rate of bone loss on serial DXA, and other individual risk factors.

How Long Does Protection Last?

The FLEX (Fracture Intervention Trial Long-Term Extension) study followed women who had completed five years of alendronate. Women who continued for a total of ten years maintained slightly higher BMD and had a significantly lower rate of clinical vertebral fractures compared with those who stopped at five years. Hip fracture rates were not significantly different between the groups at ten years, forming part of the rationale for offering drug holidays to lower-risk women after five years.

Dosing, Administration, and Common Mistakes

Standard Dosing for Postmenopausal Osteoporosis

The FDA-approved doses for postmenopausal osteoporosis are 10 mg taken orally once daily or 70 mg taken orally once weekly. The weekly formulation was developed specifically to improve adherence, and studies show the two regimens produce equivalent BMD gains. For most women in their 60s, the 70 mg once-weekly tablet is the practical standard.

Alendronate is also approved for the prevention of osteoporosis at a lower dose: 5 mg daily or 35 mg weekly. If your T-score is in the osteopenia range and your clinician wants to start therapy early, this lower dose is the indicated option.

The Absorption Problem (and How to Solve It)

Oral bioavailability of alendronate is only about 0.7% under fasting conditions and falls further if you eat or drink anything other than plain water within 30-60 minutes. The FDA prescribing information specifies that you must:

• Take the tablet with a full 240 mL (8 oz) glass of plain water only.
• Remain upright (sitting or standing) for at least 30 minutes afterward.
• Wait at least 30 minutes before eating, drinking anything else, or taking other medications.
• Never take it at bedtime or while lying down.

Skipping the upright rule is the single most common reason women develop esophageal irritation on alendronate. Barrett's esophagus and pre-existing esophageal motility problems are contraindications.

Renal Considerations in Your 60s

Kidney function commonly declines with age. Alendronate is cleared renally and is not recommended when creatinine clearance falls below 35 mL/min. If you are in your late 60s or 70s and have not had recent renal function testing, ask your provider to check before starting or continuing. For women with moderate kidney disease, IV zoledronic acid or denosumab may be preferable options.

Side Effects Specific to Women

Gastrointestinal Effects

Upper GI complaints, including heartburn, esophageal irritation, and nausea, are the most common reason women stop alendronate. The risk is higher if you have a history of GERD or hiatal hernia. Taking the medication exactly as directed substantially reduces (but does not eliminate) this risk. Some clinicians switch patients with persistent upper GI symptoms to IV zoledronic acid (Reclast) given once yearly, which bypasses the GI tract entirely.

Musculoskeletal Pain

The FDA added a warning in 2008 regarding severe, incapacitating bone, joint, and muscle pain associated with bisphosphonate use. This pain may begin days to months after starting the drug. It typically resolves after stopping, though resolution can take weeks. Women are not inherently at higher risk than men for this effect, but because women make up the vast majority of bisphosphonate users, they account for most reported cases.

Atypical Femoral Fractures (AFF)

Atypical subtrochanteric and diaphyseal femoral fractures are a recognized rare complication of long-term bisphosphonate use. The American Society for Bone and Mineral Research (ASBMR) Task Force estimated the incidence at roughly 3.2-50 cases per 100,000 person-years, rising with duration of use beyond five years. Many women describe a prodrome of dull, aching thigh pain for weeks before the fracture occurs. Report any new thigh or groin pain to your provider promptly. Bilateral X-rays of both femurs are warranted if AFF is suspected, because the condition may develop bilaterally.

Osteonecrosis of the Jaw (ONJ)

ONJ is characterized by exposed bone in the jaw that fails to heal. The risk with oral bisphosphonates used for osteoporosis is very low, estimated at 1 in 10,000 to 1 in 100,000 patient-treatment years, far lower than the risk seen with high-dose intravenous bisphosphonates used in oncology settings. Your risk increases if you have active dental disease, require invasive dental procedures, smoke, or use corticosteroids. The standard guidance from ACOG and the American Dental Association is to complete any necessary invasive dental work before starting a bisphosphonate when possible, and to inform your dentist about your bisphosphonate use before any future extraction or implant.

Drug Holidays: Who Needs One and When

A "drug holiday" means intentionally stopping alendronate for a defined period, typically 1-5 years, while residual drug in bone continues to provide some protection. The concept exists because bisphosphonates accumulate in bone for years after you stop taking them.

Who Should Consider a Holiday After 5 Years

The American Society for Bone and Mineral Research recommends reassessing fracture risk after five years of oral bisphosphonate therapy. Women who may be reasonable candidates for a holiday at five years include those with:

• A hip T-score above -2.5 at the five-year mark.
• No prior hip or vertebral fracture.
• A FRAX score below the treatment threshold.

For these women, stopping alendronate and monitoring with DXA every 2-3 years is a reasonable strategy.

Who Should Continue Beyond 5 Years

Women at high ongoing risk should generally continue, typically for up to ten years. This group includes women with:

• A hip T-score at or below -2.5 after five years.
• A prior vertebral or hip fracture.
• Ongoing high FRAX probability.
• Risk factors such as corticosteroid use, aromatase inhibitor therapy for breast cancer, or gastrointestinal malabsorption.

A practical framework for the decision: Think of it as a two-step test. First, where is your T-score now? Second, have you fractured? If both answers suggest low ongoing risk, a holiday is reasonable. If either answer suggests high risk, continuing therapy or switching to an anabolic agent (teriparatide, abaloparatide, romosozumab) before returning to a bisphosphonate is worth discussing with your provider.

Pregnancy, Lactation, and Contraception

Alendronate is contraindicated in pregnancy. This section is included because the FDA requires it in prescribing information, and because a small number of women in their early 60s retain ovarian function and residual fertility.

Pregnancy Category and Human Data

Alendronate is classified as FDA Pregnancy Category C (legacy classification), meaning animal studies show fetal harm and there are no adequate human studies. Case reports of inadvertent bisphosphonate exposure in pregnant women describe fetal skeletal abnormalities and neonatal hypocalcemia, though the data set is small. Bisphosphonates cross the placenta and incorporate into fetal bone, where they may persist for months to years. If you become pregnant while taking alendronate, stop the medication immediately and contact your obstetrician.

Lactation

Animal studies suggest bisphosphonates are excreted in breast milk. Because alendronate is not indicated in premenopausal women for osteoporosis (with rare exceptions such as glucocorticoid-induced osteoporosis), and because the drug's skeletal incorporation raises theoretical concerns about infant bone development, most clinicians advise against use during lactation. In the typical woman in her 60s, this is not a practical concern, but it is worth naming plainly.

Contraception

Alendronate is not a teratogen requiring mandatory contraception in the same category as methotrexate or thalidomide. Still, because bisphosphonates persist in bone for years and their fetal effects are not fully characterized, any woman with retained fertility who is prescribed alendronate should use reliable contraception and discuss her family-planning status with her provider before starting.

Who This Is Right For (and Who Should Look at Other Options)

Women Most Likely to Benefit

Alendronate is a strong first choice for postmenopausal women in their 60s and beyond who have:

• Established osteoporosis (T-score at or below -2.5 at hip or spine).
• A prior low-trauma fracture at the hip or vertebra.
• Osteopenia with a FRAX score meeting treatment thresholds.
• Glucocorticoid-induced osteoporosis (a separate FDA indication; dose is 5 mg daily or 10 mg daily if not on estrogen).
• Breast cancer survivors on aromatase inhibitors, who lose bone at an accelerated rate and often qualify for bisphosphonate treatment sooner than average-risk women.

Women Who Should Explore Alternatives

Alendronate may not be the right fit if you have:

• Creatinine clearance below 35 mL/min.
• Active upper GI disease, Barrett's esophagus, or severe GERD.
• Inability to remain upright for 30+ minutes after taking a tablet (relevant for women with severe mobility limitations).
• Very high fracture risk (T-score below -3.0, multiple prior fractures): anabolic agents like teriparatide (Forteo) are now preferred as first-line in this group by The Endocrine Society guidelines.
• A history of esophageal cancer or radiation to the mediastinum.

Denosumab (Prolia), given as a subcutaneous injection every six months, is an alternative oral-free option with strong fracture data. Zoledronic acid (Reclast) given as a once-yearly IV infusion suits women who cannot manage weekly oral dosing. The HORIZON Key Fracture Trial showed zoledronic acid reduced hip fracture risk by 41% and vertebral fracture risk by 70% over three years in postmenopausal women with osteoporosis.

Monitoring While You Are on Alendronate

DXA Schedule

The Endocrine Society recommends repeat DXA every 1-2 years after starting pharmacotherapy to assess response. Once your BMD has stabilized, extending the interval to 2-3 years is reasonable. A BMD loss of more than 5% at the hip on repeat DXA despite adherence should trigger a reassessment: are you taking the medication correctly, absorbing it adequately, and free of secondary causes of bone loss?

Laboratory Monitoring

Before starting, check:

• Serum calcium and 25-hydroxyvitamin D. Hypocalcemia must be corrected before you start any bisphosphonate.
• Creatinine and eGFR.
• TSH if thyroid disease is suspected, because both hypothyroidism and thyroid hormone over-replacement accelerate bone loss.

Bone turnover markers (serum CTX, urine NTX) can confirm biochemical response within 3-6 months of starting alendronate, a useful check before waiting one to two years for DXA change. A reduction in serum CTX of 50-70% from baseline is the expected response to alendronate at therapeutic doses.

Calcium and Vitamin D Co-prescription

Alendronate does not work optimally in a vitamin D-deficient environment. The National Osteoporosis Foundation recommends 1,200 mg of calcium daily (from food and supplements combined) and 800-1,000 IU of vitamin D3 daily for women over 50. Take calcium supplements at a different time of day from alendronate, because calcium (and all mineral supplements, antacids, and most medications) impairs absorption if taken within 30-60 minutes.

Special Situations in Your 60s and Beyond

Aromatase Inhibitor-Induced Bone Loss

If you are a breast cancer survivor taking an aromatase inhibitor (anastrozole, letrozole, exemestane), your bone loss rate can reach 2-3% per year at the lumbar spine, mimicking early postmenopause. ACOG and ASCO both support bisphosphonate use in this population when T-score falls below -2.0 or when fracture risk is elevated. Alendronate has been shown in multiple trials to preserve BMD during aromatase inhibitor therapy.

Corticosteroid Use

If you are taking oral prednisone at 5 mg/day or more for three months or longer, you qualify for glucocorticoid-induced osteoporosis (GIOP) prophylaxis regardless of your baseline T-score. The ACR guidelines for GIOP recommend alendronate as a first-line oral agent in postmenopausal women, at 10 mg daily or 70 mg weekly.

Falls Risk and Fracture Context

Bone density is only half the fracture equation. Falls prevention matters equally. A Cochrane review of fall prevention programs found that multifactorial interventions reduced fall rate by 24% in community-dwelling older adults. Ask your provider about a falls risk assessment, vision check, medication review for sedating drugs, and referral to physical therapy for balance and strength training. Alendronate cannot prevent a fracture from a fall it cannot predict.

Women With PCOS Entering Their 60s

Women with polycystic ovary syndrome (PCOS) have a complex bone health story. Chronic androgen excess and often-elevated BMI during reproductive years may offer some skeletal protection, but the picture shifts after menopause. A study published in the Journal of Clinical Endocrinology and Metabolism found that postmenopausal women with a history of PCOS did not have significantly different lumbar spine BMD compared with controls, though long-term fracture data specific to this group is limited. If you have PCOS and enter your 60s, standard screening and treatment thresholds apply; there is no evidence to delay or accelerate treatment compared with the general postmenopausal population.

Practical Checklist Before Your First Dose

A straightforward set of steps your clinician should run through with you:

• Confirm diagnosis (T-score, FRAX score, or prior fracture).
• Check serum 25-hydroxyvitamin D and correct deficiency to above 30 ng/mL before starting.
• Check renal function (eGFR above 35 mL/min required).
• Check serum calcium; treat hypocalcemia if present.
• Schedule dental evaluation if you have active oral disease or pending invasive dental work.
• Counsel on administration technique (upright, plain water, 30-minute wait).
• Plan first follow-up DXA at 1-2 years.
• Set a five-year reassessment date to reconsider drug holiday eligibility.

If you are already on alendronate and have never reviewed these steps with your provider, your next annual visit is the right time to revisit them.